肿瘤防治研究2013，Vol.40Issue(6)：521-524,4.DOI:10.3971/j.issn.1000-8578.2013.06.004
染色体1q21扩增对硼替佐米或沙利度胺治疗初治多发性骨髓瘤疗效的影响
Impact of 1q21 Amplification on Prognosis of Multiple Myeloma Treated with Bortezomib or Thalidomide
曾添美 1叶飞 1张春阳 1傅卫军 1李璐 2周帆 2侯健1
作者信息
- 1. 200003上海,第二军医大学长征医院血液科全军骨髓瘤与淋巴瘤疾病中心
- 2. 上海闸北区中心医院血液科
- 折叠
摘要
Abstract
Objective To analyze the correlation between the 1q21 amplification and the treatment response in patients with multiple myeloma treated with Bortezomib and/or Thalidomide.Methods Fluorescence in situ hybridization (FISH) was used to detect the 1q21 amplification in patients treated with Bortezomib and/or Thalidomide.The clinical characteristics and treatment response were also analyzed.Results Results 1q21amplification was discovered in 29 of 108 patients (26.9％).The patients with 1q21 amplification had a higher median age and lower HB concentration than those without 1q21 amplification (62y vs.58y,P=0.029 and 81.39 g/L vs.97.58 g/L,P=0.002).Other clinical characteristics such as SCr,Ca2+,ALB,β2 microglobulin,plasma cell proportion seemed to have no correlation with 1q21 amplification.The patients with 1q21 amplification had a higher rate of IgH translocation and 13q deletion (79.3 ％ vs.48.1 ％,P =0.004 and 58.6 ％ vs.31.6％,P =0.011,respectively).The treatment response was evaluable in 95 patients.The overall response rate (ORR) was 73.7％ (70/95).Twelve patients treated with both Bortezomib and Thalidomide were excluded and the remained 83 patients were divided into two groups (BOrtezomib-based and Thalidomide-based).Response rate was not significant difference between patients with and without 1q21 amplification in Bortezomib-based group,but patients with 1q21 amplification had a higher response rate than those without 1q21 amplification in Thalidomidebased group (70％ vs.80％,P =0.789 and 20％ vs.78.3％ P =0.005).Multivariate analysis showed 1q21 amplification was an independent prognostic predictor,OR(Odds Ratio) =0.231 (95％ CI:0.078-0.684,P =0.008).Conclusion 1q21 amplification was a vital predictor of prognosis as patients with 1q21 amplification had a lower response rate when treated with Thalidomide rather than Bortezomib.关键词
1q21扩增/多发性骨髓瘤/硼替佐米/沙利度胺Key words
1q21 amplification/Multiple myeloma/Bortezomib/Thalidomide分类
医药卫生引用本文复制引用
曾添美,叶飞,张春阳,傅卫军,李璐,周帆,侯健..染色体1q21扩增对硼替佐米或沙利度胺治疗初治多发性骨髓瘤疗效的影响[J].肿瘤防治研究,2013,40(6):521-524,4.
